Medivo’s solutions are driven by our clinical and analytics expertise, utilizing our proprietary patient profiles to quickly identify new areas of opportunity.
New York, NY (PRWEB) March 05, 2015
Medivo’s Co-Founder and CEO, Sundeep Bhan, will be presenting at the G2 Lab Revolution conference in Orlando, Fla. on March 13, 2015 at 11:15 AM ET during a session entitled, “The Big Deal with Big Data: Using Analytics to Unlock the Power of Lab Data.” During his presentation, Mr. Bhan will demonstrate how Medivo’s data analytics highlight opportunities to improve the outcomes of chronic myelogenous leukemia (“CML”) patients through outreach and education.
Immediately following, Mr. Bhan will also participate on a panel entitled, “Survive and Thrive: Growth Strategies for an Evolving Marketplace” at 12:00 PM ET.
Representatives from Medivo will be on hand throughout the conference at booth #202. Conference attendees can receive information about Medivo’s recently launched CLEAR™ Data Solutions for Labs, a platform that helps lab partners identify new revenue opportunities, as well as improve performance and quality.
“With the addition of CLEAR solutions, our lab partners can capture additional revenue by identifying accounts that may not be testing to guidelines. Medivo’s solutions are driven by our clinical and analytics expertise, utilizing our proprietary patient profiles to quickly identify new areas of opportunity,” noted Mr. Bhan. “We look forward to offering these solutions in addition to our lab data commercialization services.”
About G2 Lab Revolution
G2 Lab Revolution is an annual four-day conference for clinical laboratory administrators and pathologists who are interested in new and innovative business models, critical market trends, and practical solutions that are boosting bottom-line performance while conveying the value proposition of diagnostic medicine. G2 Lab Revolution is hosted by G2 Intelligence, a division of Kennedy Information, LLC, a leading provider of professional markets analysis. Kennedy’s parent company, Bloomberg BNA, a wholly owned subsidiary of Bloomberg, is a leading source of legal, regulatory, and business information for professionals. To learn more about G2 Lab Revolution, please visit http://www.labrevolution.com.
Medivo's mission is to improve the health of patients by using lab data and analytics to enable better treatment decisions. Medivo’s clinical data experts extract proprietary insights from the Medivo Lab Value Exchange™(LVX™), an anonymized clinical database of more than 30 million patients and more than 130M test results. Medivo enables life science companies to build clinical intelligence to optimize their sales and marketing initiatives, while enabling its lab partners to realize the full value of their data assets and to gain value with their customers through Medivo’s Lab Solutions. Founded in 2010 by healthcare entrepreneurs, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.